Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(+) T-cell responses which can be defined to the epitope level.

Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, Grohskopf LA, Grant RM, Nixon DF.

Clin Vaccine Immunol. 2008 Nov;15(11):1745-8. doi: 10.1128/CVI.00247-08. Epub 2008 Sep 24.

2.

Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes.

Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, Hentze JL, Andresen BS, Svane IM, Gerstoft J, Kronborg G, Fomsgaard A.

AIDS. 2009 Jul 17;23(11):1329-40. doi: 10.1097/QAD.0b013e32832d9b00.

PMID:
19528789
3.

Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection.

Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N, Honeyborne I, Crawford H, Coovadia HM, Goulder PJ, Walker BD, Klenerman P.

J Virol. 2007 Jan;81(1):434-8. Epub 2006 Oct 18.

4.

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.

Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD; HIV Controller Study Collaboration.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6.

5.

Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation.

Sheth PM, Sunderji S, Shin LY, Rebbapragada A, Huibner S, Kimani J, Macdonald KS, Ngugi E, Bwayo JJ, Moses S, Kovacs C, Loutfy M, Kaul R.

J Infect Dis. 2008 May 15;197(10):1394-401. doi: 10.1086/587697.

PMID:
18444797
6.

Identification of a novel HLA-B-35-restricted cytotoxic T-lymphocyte epitope within human immunodeficiency type 1 (HIV-1) P17(Gag).

M'Bika JP, Achour A.

Immunol Lett. 2002 Oct 1;83(3):149-50. No abstract available.

PMID:
12095703
7.

A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef.

Navis M, Schellens IM, van Swieten P, Borghans JA, Miedema F, Kootstra NA, van Baarle D, Schuitemaker H.

J Infect Dis. 2008 Mar 15;197(6):871-9. doi: 10.1086/528695.

PMID:
18279072
8.

Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection.

Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, Rosenberg ES, Walker BD, Altfeld M.

J Virol. 2007 Apr;81(8):4199-214. Epub 2007 Feb 7.

9.

Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals.

Mendiratta S, Vajpayee M, Malhotra U, Kaushik S, Dar L, Mojumdar K, Chauhan NK, Sreenivas V.

Med Microbiol Immunol. 2009 Feb;198(1):47-56. doi: 10.1007/s00430-008-0104-3. Epub 2008 Nov 5.

PMID:
18985383
10.

Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.

Cukalac T, Moffat JM, Venturi V, Davenport MP, Doherty PC, Turner SJ, Stambas J.

Vaccine. 2009 Nov 12;27(48):6755-61. doi: 10.1016/j.vaccine.2009.08.079. Epub 2009 Sep 8.

PMID:
19744584
11.

[Immunodominance in CD8+ T cell responses to HIV-1 synthesized epitopes].

Tang YB, Tang XP, Jin X.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Sep;21(3):217-9. Chinese.

PMID:
17971925
12.
13.

Cross-clade CD8(+) T-cell responses with a preference for the predominant circulating clade.

McKinnon LR, Ball TB, Kimani J, Wachihi C, Matu L, Luo M, Embree J, Fowke KR, Plummer FA.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):245-9.

PMID:
16249696
14.

Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy.

Wilson CC, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Schooley RT, Benson CA.

Clin Vaccine Immunol. 2008 Jun;15(6):986-94. doi: 10.1128/CVI.00492-07. Epub 2008 Apr 9.

15.

De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection.

Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, Cheng M, Allgaier RL, Mui S, Frahm N, Alter G, Brown NV, Johnston MN, Rosenberg ES, Mallal SA, Brander C, Walker BD, Altfeld M.

J Virol. 2005 Oct;79(20):12952-60.

16.

Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.

Payne RP, Kløverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ.

J Virol. 2010 Oct;84(20):10543-57. doi: 10.1128/JVI.00793-10. Epub 2010 Aug 4.

17.
18.

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B, Letvin NL, Walker BD, Hahn BH, Korber BT.

Nat Med. 2007 Jan;13(1):100-6. Epub 2006 Dec 24.

PMID:
17187074
19.

Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.

Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HF Jr, Martin JN, Deeks SG, Shacklett BL.

J Virol. 2010 Oct;84(19):10354-65. doi: 10.1128/JVI.00803-10. Epub 2010 Jul 28.

20.

Impact of Gag sequence variability on level, phenotype, and function of anti-HIV Gag-specific CD8(+) cytotoxic T lymphocytes in untreated chronically HIV-infected patients.

López M, Soriano V, Lozano S, Martinez P, Sempere J, González-Lahoz J, Benito J.

AIDS Res Hum Retroviruses. 2006 Sep;22(9):884-92.

PMID:
16989614

Supplemental Content

Support Center